Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up of AS patients in the phase III ASTERA study.

Objective: to study the efficacy and safety of NTK when used long in patients with active AS.

Patients and methods. The investigation enrolled 228 patients with active AS, in whom nonsteroidal anti-inflammatory drugs or biological agents were ineffective. The patients were randomized in a 1:1 ratio to receive NTK 120 mg or placebo. The drug was administered subcutaneously at weeks 0, 1, 2, and then once every 2 weeks. Patients who received placebo and achieved a 20% improvement according to the ASAS criteria (ASAS20) were excluded from the study at week 16. At this week, patients who took placebo and did not achieve an ASAS20 response were switched to subcutaneous NTK at 120 mg dose once every two weeks. The follow-up period was 52 weeks.

Results and discussion. Patients with active AS who received NTK were more likely to respond to treatment than those who took placebo. The proportion of people who achieved 40% improvement (ASAS40) during treatment with NTK increased throughout the follow-up period and amounted to 80.7% at week 52. Positive changes were achieved in all used clinical and laboratory parameters of AS activity. There was also a decrease in inflammatory changes, as shown by magnetic resonance imaging (MRI). The adverse events (AEs) were mainly laboratory abnormalities and upper respiratory tract infections. Treatment-related AEs were recorded in no more than one third of patients and they were mild to moderate. Severe AEs were singular.

Conclusion. Response to NTK therapy generates in the first weeks of drug use and increases throughout a year. The safety profile of NTK when used long is generally favorable.

1. Rumyantseva DG, Erdes SF. Axial spondyloarthritis: a current look at the concept and evolution of the disease. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(4):4-10 (In Russ.). doi: 10.14412/1996-7012-2019-4-4-10.

2. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-91. doi: 10.1136/annrheumdis2016-210770. Epub 2017 Jan 13.

3. Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):707-18. doi: 10.1038/nrrheum.2017.187.

4. Owczarczyk-Saczonek A, Owczarek W, Osmola-Mankowska A, et al. Secondary Failure of TNF-α Inhibitors in Clinical Practice. Dermatol Ther. 2019 Jan; 32(1):e12760. doi: 10.1111/dth.12760. Epub 2018 Nov 18.

5. Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066.

6. Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, DoubleBlind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2019 Apr; 71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8.

7. Van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, doubleblind, active-controlled and placebo-controlled trial. Lancet. 2018 Dec 8;392(10163): 2441-51. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

8. Kaushik S, Lebwohl M. Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies. Int J Dermatol. 2019 Jun; 58(6):649-58. doi: 10.1111/ijd.14246. Epub 2018 Sep 23.

9. Kubanov AA, Bakulev AL, Samtsov AV, et al. Netakimab – new IL-17a inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-to-severe plaque psoriasis. Vestnik Dermatologii i Venerologii. 2019;95(2):15-28. (In Russ.).

10. Korotaeva T, Gaydukova I, Mazurov V, et al. OP0226 Netakimab decreases disease activity in patients with psoriatic arthritis: results from a randomized double-blind phase 3 clinical trial (PATERA). Ann Rheum Dis. 2020;79(Suppl 1):141-2. doi: 10.1136/annrheumdis-2020-eular.3469.

11. Mazurov VI, Gaidukova IZ, Erdes Sh, et al. Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Nauchno-prakticheskaya revmatologiya. 2020;58(4):376-86. (In Russ.).

12. Garrett S, Jenkinson T, Kennedy L, et al. A New Approach to Defining Disease Status in Ankylosing Spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12): 2286-91.

13. Anderson J, Baron G, van der Heijde D, et al. Ankylosing Spondylitis Assessment Group Preliminary Definition of Short-Term Improvement in Ankylosing Spondylitis. Arthritis Rheum. 2001 Aug;44(8):1876-86. doi: 10.1002/1529-0131(200108)44:8 <1876::AID-ART326>3.0.CO;2-F.

14. Brandt J, Listing J, Sieper J, et al. Development and Preselection of Criteria for Short Term Improvement After anti-TNF Alpha Treatment in Ankylosing Spondylitis. Ann Rheum Dis. 2004 Nov;63(11):1438-44. doi: 10.1136/ard.2003.016717. Epub 2004 Mar 25.

15. Machado P, Navarro-Compan V, Landewe R, et al. Calculating the Ankylosing Spondylitis Disease Activity Score if the Conventional C-Reactive Protein Level Is Below the Limit of Detection or if HighSensitivity C-Reactive Protein Is Used: An Analysis in the DESIR Cohort. Arthritis Rheumatol. 2015 Feb;67(2):408-13. doi: 10.1002/art.38921.

16. Calin A, Garrett S, Whitelock H, et al. A New Approach to Defining Functional Ability in Ankylosing Spondylitis: The Development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281-5.

17. Jones S, Porter J, Garrett S, et al. A New Scoring System for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol. 1995 Aug;22(8):1609.

18. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003 Feb;62(2):127-32. doi: 10.1136/ard. 62.2.127.

19. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992 Jul 18;305(6846):160-4. doi: 10.1136/bmj.305.6846.160.

20. Lukas C, Braun J, van der Heijde D, et al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol. 2007 Apr;34(4):862-70.

21. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2005 Aug 15;53(4):502-9. doi: 10.1002/art.21337.

22. Creemers MCW, Franssen MJAM, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005 Jan;64(1):127-9. doi: 10.1136/ard.2004. 020503. Epub 2004 Mar 29.

23. Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017 Jun;76(6):1070-77. doi: 10.1136/annrheumdis-2016-209730. Epub 2016 Dec 13.

24. Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-29. doi: 10.1002/acr.23233. Epub 2017 Jun 7.

25. Dougados M, Wei JC-C, Landewe R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020 Feb;79(2):176-85. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4.

26. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients With Ankylosing Spondylitis: A Randomized Clinical Trial. Arthritis Rheum. 2005 Jun; 52(6):1756-65. doi: 10.1002/art.21054.

27. Sieper J, Listing J, Poddubnyy D, et al. Effect of Continuous Versus On-Demand Treatment of Ankylosing Spondylitis With Diclofenac Over 2 Years on Radiographic Progression of the Spine: Results From a Randomised Multicentre Trial (ENRADAS). Ann Rheum Dis. 2016 Aug;75(8):1438-43. doi: 10.1136/annrheumdis-2015-207897. Epub 2015 Aug 4.

28. Aouad K, Ziade N, Baraliakos X. Structural Progression in Axial Spondyloarthritis. Joint Bone Spine. 2020 Mar;87(2):131-6. doi: 10.1016/j.jbspin. 2019.04.006. Epub 2019 May 5. 29. Schett G, Lories R, D'Agostino M, et al. Enthesitis: From Pathophysiology to Treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):731-41. doi: 10.1038/nrrheum.2017.188.